Short Ragweed Pollen Allergen (Amb a)

Ragweed pollen allergens, primarily from the species Ambrosia artemisiifolia, are potent environmental triggers for seasonal allergic rhinitis and allergic asthma (National Institute of Allergy and Infectious Diseases [NIAID]). The adaptive immune system's response to these allergens is dominated by the major protein Amb a 1, a pectate lyase that induces the production of allergen-specific IgE antibodies (UniProt P27759; Wopfner et al., 2005). These IgE antibodies bind to high-affinity receptors on mast cells and basophils, leading to Type I hypersensitivity reactions upon subsequent allergen exposure (StatPearls, 2023). Therapeutic management often utilizes allergen-specific immunotherapy (AIT), such as the FDA-approved sublingual tablet Ragwitek, which contains standardized Short Ragweed Pollen Allergen Extract (FDA, 2014). The mechanism of action for AIT involves shifting the immune profile from a Th2-driven allergic response to a regulatory T cell (Treg) and Th1-driven tolerant state (Akdis & Akdis, 2014). This immunological reprogramming is characterized by increased levels of IL-10 and allergen-specific IgG4, which acts as a blocking antibody to prevent IgE-allergen binding. This process reduces the inflammatory response and provides long-term clinical benefit beyond the duration of treatment. However, the administration of these allergens carries a risk of systemic allergic reactions, including anaphylaxis, necessitating careful patient selection and monitoring (PubMed, 2020).

Other names

Ambrosia artemisiifolia allergensShort ragweed extractAmb a 1Ragweed pollen extract

Allergen-specific immunotherapy (AIT) induces immune tolerance by promoting the development of regulatory T cells (Tregs) and the production of blocking antibodies like IgG4, which prevent IgE-mediated mast cell degranulation (Akdis & Akdis, 2014; FDA, 2014).